Italy Fines Apple €98.6 Million Over App Store Dominance 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
LAGUNA HILLS, Calif., April 12, 2016 -- Sonendo®, Inc., the developer of a disruptive technology for the endodontic marketplace, announced today that they will attend the April 2016 Needham & Company’s 15th Annual Healthcare Conference in New York City.
On Wednesday, April 13th, at 9:40 a.m. Eastern Time, Sonendo® President and CEO, Bjarne Bergheim, will present a company overview and update on the GentleWave® System. About the event Bjarne Bergheim stated, “Sonendo is developing exponential technological advancements in Root Canal Therapy that improve patient outcomes and I look forward to sharing our story and milestones at this year’s conference.”
About Sonendo®
Sonendo, Inc. is a privately-held, venture-backed company developing innovative and disruptive technologies to transform dentistry by Saving Teeth Through Sound Science®. The first commercially available product from Sonendo, the GentleWave® System, available in the US, shows significant improvements in clinical efficacy, and treatment efficiency when compared to conventional root canal techniques1-2. For more information please visit: www.sonendo.com.
1Molina B et al. (2015) J Endod. 41:1701-05. 2Haapasalo M et al. (2014) J Endod. 40:1178-81.
Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
Media Contact: Bob Guyatt Vice President of Marketing 949.766.3636
